Cargando…

Immune signature as predictive marker for response to checkpoint inhibitor immunotherapy and overall survival in melanoma

BACKGROUND: Malignant melanoma is an immunogenic skin cancer with an increasing global incidence. Advanced stages of melanoma have poor prognoses. Currently, there are no reliable parameters to predict a patient's response to immune checkpoint inhibitor (ICI) therapy. METHODS: This study highli...

Descripción completa

Detalles Bibliográficos
Autores principales:	Krebs, Franziska K., Trzeciak, Emily R., Zimmer, Sophia, Özistanbullu, Deniz, Mitzel‐Rink, Heidrun, Meissner, Markus, Grabbe, Stephan, Loquai, Carmen, Tuettenberg, Andrea
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7940230/ https://www.ncbi.nlm.nih.gov/pubmed/33449393 http://dx.doi.org/10.1002/cam4.3710

Ejemplares similares

Platelet-Derived GARP Induces Peripheral Regulatory T Cells—Potential Impact on T Cell Suppression in Patients with Melanoma-Associated Thrombocytosis
por: Zimmer, Niklas, et al.
Publicado: (2020)

Long-lasting tumor response on short-time administration of vemurafenib—A case report
por: Mitzel, Heidrun, et al.
Publicado: (2014)

T-cell response to checkpoint blockade immunotherapies: from fundamental mechanisms to treatment signatures
por: Elliot, Thomas A.E., et al.
Publicado: (2023)

Anticoagulation with Factor Xa Inhibitors Is Associated with Improved Overall Response and Progression-Free Survival in Patients with Metastatic Malignant Melanoma Receiving Immune Checkpoint Inhibitors—A Retrospective, Real-World Cohort Study
por: Haist, Maximilian, et al.
Publicado: (2021)

Identification of a thirteen-gene signature predicting overall survival for hepatocellular carcinoma
por: Zhou, Xiaohan, et al.
Publicado: (2021)

The Role of Treatment Sequencing with Immune-Checkpoint Inhibitors and BRAF/MEK Inhibitors for Response and Survival of Patients with BRAFV600-Mutant Metastatic Melanoma—A Retrospective, Real-World Cohort Study
por: Haist, Maximilian, et al.
Publicado: (2022)

Immune implication of an autophagy-related prognostic signature in uveal melanoma
por: Chuah, Samuel, et al.
Publicado: (2021)

Progression patterns under BRAF inhibitor treatment and treatment beyond progression in patients with metastatic melanoma
por: Hassel, Jessica C., et al.
Publicado: (2017)

Uronic acid metabolic process–related gene expression–based signature predicts overall survival of glioma
por: Feng, Yuemei, et al.
Publicado: (2021)

BRAF inhibitors stimulate inflammasome activation and interleukin 1 beta production in dendritic cells
por: Hajek, Eva, et al.
Publicado: (2018)

Oxidative Stress Differentially Influences the Survival and Metabolism of Cells in the Melanoma Microenvironment
por: Trzeciak, Emily R., et al.
Publicado: (2022)

Checkpoint blockade‐based immunotherapy in the context of tumor microenvironment: Opportunities and challenges
por: Duan, Jingjing, et al.
Publicado: (2018)

Functional Downregulation of PD-L1 and PD-L2 by CpG and non-CpG Oligonucleotides in Melanoma Cells
por: Kleemann, Johannes, et al.
Publicado: (2022)

Impact of a preceding radiotherapy on the outcome of immune checkpoint inhibition in metastatic melanoma: a multicenter retrospective cohort study of the DeCOG
por: Knispel, Sarah, et al.
Publicado: (2020)

Baseline Serum Autoantibody Signatures Predict Recurrence and Toxicity in Melanoma Patients Receiving Adjuvant Immune Checkpoint Blockade
por: Johannet, Paul, et al.
Publicado: (2022)

The efficacy of re-challenge with BRAF inhibitors after previous progression to BRAF inhibitors in melanoma: A retrospective multicenter study
por: Tietze, Julia K., et al.
Publicado: (2018)

GARP as a Therapeutic Target for the Modulation of Regulatory T Cells in Cancer and Autoimmunity
por: Zimmer, Niklas, et al.
Publicado: (2022)

Improving the overall survival prognosis prediction accuracy: A 9‐gene signature in CRC patients
por: Zheng, Wenbo, et al.
Publicado: (2021)

Signature based on metabolic‐related gene pairs can predict overall survival of osteosarcoma patients
por: Li, Long‐Qing, et al.
Publicado: (2021)

Impact of the Covid‐19 pandemic on melanoma and non‐melanoma skin cancer inpatient treatment in Germany – a nationwide analysis
por: Kleemann, J., et al.
Publicado: (2022)

Immune‐related signature predicts the prognosis and immunotherapy benefit in bladder cancer
por: Wang, Yejinpeng, et al.
Publicado: (2020)

Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patients
por: Amaral, Teresa, et al.
Publicado: (2020)

Correlation of tumor‐infiltrating immune cells of melanoma with overall survival by immunogenomic analysis
por: Huang, Lili, et al.
Publicado: (2020)

Effect of cyclo-oxygenase inhibitor use during checkpoint blockade immunotherapy in patients with metastatic melanoma and non-small cell lung cancer
por: Wang, Shang-Jui, et al.
Publicado: (2020)

Modern Aspects of Immunotherapy with Checkpoint Inhibitors in Melanoma
por: Petrova, Vera, et al.
Publicado: (2020)

Modulatory effects of gut microbiome in cancer immunotherapy: A novel paradigm for blockade of immune checkpoint inhibitors
por: Rezasoltani, Sama, et al.
Publicado: (2020)

Pituitary dysfunction induced by immune checkpoint inhibitors is associated with better overall survival in both malignant melanoma and non-small cell lung carcinoma: a prospective study
por: Kobayashi, Tomoko, et al.
Publicado: (2020)

Characterization of genetics in patients with mucosal melanoma treated with immune checkpoint blockade
por: Buchbinder, Elizabeth I., et al.
Publicado: (2021)

Metastatic melanoma patient outcomes since introduction of immune checkpoint inhibitors in England between 2014 and 2018
por: Board, Ruth, et al.
Publicado: (2020)

Development of an IFNγ response‐related signature for predicting the survival of cutaneous melanoma
por: Hu, Baohui, et al.
Publicado: (2020)

The Status of Adjuvant and Neoadjuvant Melanoma Therapy, New Developments and Upcoming Challenges
por: Stege, Henner, et al.
Publicado: (2021)

Checkpoint therapeutic target database (CKTTD): the first comprehensive database for checkpoint targets and their modulators in cancer immunotherapy
por: Zhang, Yixiao, et al.
Publicado: (2020)

Immunotherapy for Melanoma: The Significance of Immune Checkpoint Inhibitors for the Treatment of Advanced Melanoma
por: Fujimura, Taku, et al.
Publicado: (2022)

Activation of G protein-coupled estrogen receptor signaling inhibits melanoma and improves response to immune checkpoint blockade
por: Natale, Christopher A, et al.
Publicado: (2018)

No Overall Survival Difference in the Immunotherapy Era for Rare Subtypes of Melanoma
por: Safi, Mohammed, et al.
Publicado: (2021)

Endocrine‐related adverse events associated with immune‐checkpoint inhibitors in patients with melanoma
por: Kassi, Eva, et al.
Publicado: (2019)

Efficacy of novel immunotherapy regimens in patients with metastatic melanoma with germline CDKN2A mutations
por: Helgadottir, Hildur, et al.
Publicado: (2020)

Angiopoietin-2–Dependent Spatial Vascular Destabilization Promotes T-cell Exclusion and Limits Immunotherapy in Melanoma
por: Park, Ha-Ram, et al.
Publicado: (2023)

Neoadjuvant checkpoint inhibitor immunotherapy for resectable mucosal melanoma
por: Ho, Joel, et al.
Publicado: (2022)

Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study
por: Heppt, Markus V., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_i1j1m5ldjjo4vj36blmq1v86o8